However, the secretion of IL-8 induced by NOD2 agonists was lower in COVID-19 patients, indicating that NOD2 may contribute to immunosuppression after hyperinflammation in COVID-19 disease [80]. This evidence concerns the gene NOD2 and COVID-19.